Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
about
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationThalidomide analogues as anticancer drugsThalidomide-induced teratogenesis: history and mechanismsSelective leukemic-cell killing by a novel functional class of thalidomide analogsIn vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cellsPolyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cellsComparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histologyPreformulation study of NSC-726796Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.Isoindolone derivative QSN-10c induces leukemic cell apoptosis and suppresses angiogenesis via PI3K/AKT signaling pathway inhibition.Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
P2860
Q24653215-8F157BF1-3CAE-43B3-A123-0A4873133ED5Q24670383-9707AB13-FBA3-4C1C-86F5-8326F45611F6Q28085087-409031BB-6992-4337-B1FF-A7FB93BD4224Q30479632-BF466BF8-EF05-4BA5-A753-DD7C2F6E1DD2Q33552178-3FDFBAF6-652F-4EA9-BEE7-16987A09DE81Q33986673-D055EC6A-866C-47BF-917E-96C50FF47B17Q34094154-2D34DF41-4637-4FD7-9430-BEB00B9EC515Q34768926-59698CD7-364E-4ADD-9A99-AB0424DF8BFCQ35999066-A2A46029-6650-444E-AFDE-DF8C0FA84D2AQ36132803-E30893AD-675D-4FB0-A0B5-877176C5AEB9Q37117375-EAE9E2A5-67CA-4CDD-9897-EE503CEA59BCQ37424813-48F50D41-0B62-4BF3-A37B-42CD8F14360CQ38649220-DE00B756-5FE6-42E1-A367-20FE3FCFD0B9Q38999829-5999CC75-B6CA-4358-B0C9-CDFEDC0F93DDQ43410555-D00C84F6-1192-4BBC-A44B-58F73B972655
P2860
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@en
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@nl
type
label
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@en
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@nl
prefLabel
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@en
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@nl
P2093
P1433
P1476
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
@en
P2093
Erwin A Kruger
Frederick A Luzzio
Michael Gütschow
Michael Weiss
Sunna Hauschildt
Sylvia S W Ng
Thomas K Hecker
Uwe Teubert
William D Figg
P304
P407
P577
2003-06-01T00:00:00Z